David H. Fine, PhD
Chief Executive Officer
Dr. David Fine is the Chief Executive Officer of GeNO LLC, and is also its Founder. He also serves as GeNO’s Chief Technology Officer. Dr. Fine has 40 years of experience leading innovation development and transitioning high technology chemistry-based instruments from research through production and commercialization.
In 2000, Dr. Fine co-founded CyTerra Corporation where advanced technology was developed and then rapidly transitioned to production for the US military. He led
CyTerra through the accelerated development of the US Army’s new hand-held detector for buried land mines, the AN-PSS-14, and was responsible for the accelerated transition to initial production of the EMMDAR hand-held through-wall sensor. CyTerra was sold to L3-Communications in March 2006.
During his 28 year tenure at Thermo Electron, Dr. Fine was responsible for the development of numerous instrumentation systems, 11 of which were based on nitric oxide chemistry similar to GeNO’s Nitric Oxide Delivery platform. These included developing the TEA analyzer for the detection of nitrosamines, detectors for liquid rocket fuel leaks and development of the first trace explosive detectors for forensic analysis and airport security. Dr. Fine held various leadership positions at Thermo, including Vice President of Thermedics Inc. and Senior Vice President of Thermedics Detection Inc., both of which were publicly-traded subsidiaries. His last assignment at Thermo was as President of Thermo Electron’s R&D Center Inc. Dr. Fine has published over 100 technical papers in the refereed technical literature, including Nature and Science. He is also the inventor on 69 issued US patents including over 45 patents on NO/NO2 based instrumentation..
Kurt Dasse, PhD
Dr. Kurt A. Dasse has spent nearly three decades conducting research in cardiovascular disorders and developing medical devices, including products to treat heart and renal failure. He most recently served as President and CEO of a Waltham, Massachusetts based technology company, Levitronix, LLC, a developer and manufacturer of a new generation of blood pumps for the medical industry, and ultra-pure fluid handling components for the semiconductor industry. Dr. Dasse joined Levitronix in 2001 as the Chief Technical Officer, and became President & CEO of its Medical Division in 2006. He currently serves as President of GeNO and is a Director of the Company. Previously, Dr. Dasse was Chief Scientist and Vice President of $700-million Thermo Electron Corporation’s Biomedical Group, where the company focused on developing products for the respiratory, neurodiagnostic, cardiovascular and imaging markets. He also was one of the founding officers of Thermo Cardiosystems and played a key role in commercializing the first implantable ventricular assist system for end-stage heart-failure patients. Dr. Dasse is currently President of ASAIO, a society that is focused on the development of artificial organs and tissue engineering technology. He is Vice President of the International Society of Rotary Blood Pumps and on the Scientific Advisory Board for Alcresta located in Newton, Massachusetts. Dr. Dasse received his doctorate in physiology from Boston University. He has written more than100 journal articles and multiple book chapters, and holds multiple patents.
Robert F. Roscigno, PhD
Dr. Robert Roscigno brings to GeNO a broad experience in drug development and commercialization. His therapeutic specialties include pulmonary and cardiovascular drugs, among others. Dr. Roscigno previously served as President and COO of Lung Rx, Inc., an affiliate company of United Therapeutics (NASDAQ: UTHR) where he led the company’s growth from 1 to 50 employees, managing five concurrent drug development programs. He was responsible for building the product pipeline and bringing the company’s lead product, Treprostinil Sodium for Inhalation, successfully through Phase III development. Prior to Lung Rx, Dr. Roscigno served as Director, Vice President and Senior Vice-President of United Therapeutics Corporation where he helped transform the company from a start-up to a multi-billion dollar company. He directed six products in United Therapeutic’s portfolio, launched winning marketing campaigns, negotiated with Medicare and dramatically reduced overhead costs resulting in average growth of 30% – one of the highest rates for a US biotech company. Dr. Roscigno has a PhD in Microbiology and Immunology from Duke University and a BS in Biology from Trinity College. He has published numerous peer- reviewed articles and holds several US patents.
Barry Gellman, PhD
Senior Vice-President of Engineering
Mr. Barry Gellman has 38 years of product development, business development and management experience in the medical device field in the areas of Cardiopulmonary support, Cardiac & Thoracic Surgery, Urology, Gynecology, Cardiology, Mechanical Wound Closure, In-vitro Diagnostics, and GI Endoscopy. He served as Sr. Director R&D with Thoratec Corporation focused on acute and chronic extracorporeal long term cardiac support devices; and Vice President, Engineering at Levitronix LLC developing pediatric blood pump, blood oxygenators and surgical cannulae. In addition, he held management positions at Boston Scientific Corporation, Deknatel, C.R. Bard. Mr. Gellman built and managed multidisciplinary teams with emphasis in opportunity analysis, concept generation, and driving execution of product & process development of disposable & hardware products, implants and instrumentation targeted for worldwide distribution as well as inventor on 94 US patents. He holds a Bachelor of Science from Newark College of Engineering in Mechanical Engineering and a Master of Science from New Jersey Institute of Technology with a major in Mechanical Biomedical Engineering.
Jack Whiting, JD, MBA
General Counsel & Vice-President of Administration
Mr. Whiting, Vice-President of Administration, responsible for finance, legal, human resources and risk management functions, as well as supply chain management. Mr. Whiting has 25 years of experience with medical device and services companies, providing business and legal support for product development and commercialization, and organizational and transactional matters. He was formerly Vice-President and General Counsel at Levitronix, LLC, a developer of medical devices including mechanical circulatory support and respiratory support systems. Jack also previously served as Vice-President and General Counsel at a renal dialysis services provider and as Associate General Counsel at Thermo Electron Corporation. Mr. Whiting received a JD from Boston University School of Law and an MBA from F.W. Olin Graduate School of Business at Babson College.
Vice-President Regulatory Affairs
• Over 25 years of experience in regulatory affairs, quality assurance and compliance in the pharmaceutical and medical device industries
• Expertise includes drug and device approvals and developing quality systems
Vice-President Quality Assurance
• Over 20 years of diversified quality, regulatory, operational and development experience in the medical device industry
• Formerly Director of Quality Assurance and Regulatory Compliance at LightLab Imaging
• Previously employed by large medical device companies such as Medtronic and C.R. Bard
Vice-President European Sales & Marketing
• Over 20 years of clinical and sales and marketing experience with medical device companies
• Formerly Vice-President of Sales and Marketing for Levitronix, LLC
• Previously employed by ThermoCardio Systems Inc., and by St. Judes Medical